JP2024525959A - ランチオニン合成酵素C様タンパク質(LanCL)に結合可能なペプチド組成物およびその使用 - Google Patents

ランチオニン合成酵素C様タンパク質(LanCL)に結合可能なペプチド組成物およびその使用 Download PDF

Info

Publication number
JP2024525959A
JP2024525959A JP2024504021A JP2024504021A JP2024525959A JP 2024525959 A JP2024525959 A JP 2024525959A JP 2024504021 A JP2024504021 A JP 2024504021A JP 2024504021 A JP2024504021 A JP 2024504021A JP 2024525959 A JP2024525959 A JP 2024525959A
Authority
JP
Japan
Prior art keywords
peptide
group
amino acid
absent
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024504021A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525959A5 (cg-RX-API-DMAC10.html
Inventor
アンドリュー、ギアリング
デイビッド、ケンリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lateral IP Pty Ltd
Original Assignee
Lateral IP Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2021902267A external-priority patent/AU2021902267A0/en
Application filed by Lateral IP Pty Ltd filed Critical Lateral IP Pty Ltd
Publication of JP2024525959A publication Critical patent/JP2024525959A/ja
Publication of JP2024525959A5 publication Critical patent/JP2024525959A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
JP2024504021A 2021-07-23 2022-07-22 ランチオニン合成酵素C様タンパク質(LanCL)に結合可能なペプチド組成物およびその使用 Pending JP2024525959A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2021902267A AU2021902267A0 (en) 2021-07-23 Compositions and uses thereof
AU2021902267 2021-07-23
PCT/AU2022/050778 WO2023000038A1 (en) 2021-07-23 2022-07-22 Peptide compositions capable of binding lanthionine synthetase c-like protein (lancl) and uses thereof

Publications (2)

Publication Number Publication Date
JP2024525959A true JP2024525959A (ja) 2024-07-12
JP2024525959A5 JP2024525959A5 (cg-RX-API-DMAC10.html) 2025-07-29

Family

ID=84980448

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024504021A Pending JP2024525959A (ja) 2021-07-23 2022-07-22 ランチオニン合成酵素C様タンパク質(LanCL)に結合可能なペプチド組成物およびその使用

Country Status (8)

Country Link
US (1) US20250263435A1 (cg-RX-API-DMAC10.html)
EP (1) EP4373509A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024525959A (cg-RX-API-DMAC10.html)
KR (1) KR20240036634A (cg-RX-API-DMAC10.html)
CN (1) CN117813105A (cg-RX-API-DMAC10.html)
AU (1) AU2022316237A1 (cg-RX-API-DMAC10.html)
CA (1) CA3226259A1 (cg-RX-API-DMAC10.html)
WO (1) WO2023000038A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7751583B2 (ja) * 2019-12-27 2025-10-08 ラテラル、アイピー、プロプライエタリー、リミテッド 環状ペプチド受容体ランチオニンシンテターゼc様タンパク質(lancl)及びその使用

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010530215A (ja) * 2007-05-30 2010-09-09 オークランド ユニサービシス リミテッド 成長ホルモンおよび関連ホルモンの阻害剤、ならびにそれらの使用方法
JP2011527560A (ja) * 2008-01-22 2011-11-04 アライム ファーマシューティカルズ,インコーポレーテッド 組織の損傷に関連した疾患及び障害を予防及び治療する、組織保護ペプチド及びペプチド類似体
US20180143202A1 (en) * 2016-08-05 2018-05-24 Sera Prognostics, Inc. Biomarkers for predicting preterm birth in a pregnant female exposed to progestogens
WO2019183686A1 (en) * 2018-03-29 2019-10-03 Lateral IP Pty Ltd Cyclic peptides and uses thereof
WO2020068990A1 (en) * 2018-09-26 2020-04-02 California Institute Of Technology Adeno-associated virus compositions for targeted gene therapy
JP2020511633A (ja) * 2017-02-22 2020-04-16 ヘルステル・インコーポレイテッドHealthtell Inc. 感染のスクリーニング方法
EP3671210A1 (en) * 2018-12-21 2020-06-24 Biosystems International KFT Lung cancer protein epitomic biomarkers
RU2731919C1 (ru) * 2020-03-25 2020-09-09 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ коррекции микроциркуляции в плаценте пептидом, имитирующим альфа-спираль B эритропоэтина, при ADMA-подобной модели преэклампсии
JP2021510731A (ja) * 2018-01-15 2021-04-30 ラテラル、アイピー、プロプライエタリー、リミテッドLateral Ip Pty Ltd ペプチドおよびその使用
WO2021127752A1 (en) * 2019-12-27 2021-07-01 Lateral IP Pty Ltd Cyclic peptide receptor lanthionine synthetase c-like protein (lancl) and uses thereof
RU2751964C1 (ru) * 2021-02-17 2021-07-21 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ снижения агрегационной способности тромбоцитов

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638911B1 (en) * 1998-05-05 2003-10-28 Adherex Technologies Inc. Compounds and methods for modulating desmosomal cadherin-mediated functions
AUPQ981700A0 (en) * 2000-09-01 2000-09-28 Metabolic Pharmaceuticals Limited Product and method for control of obesity
WO2007068039A1 (en) * 2005-12-12 2007-06-21 Metabolic Pharmaceuticals Limited Treatment of weight gain in estrogen deficient mammals

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010530215A (ja) * 2007-05-30 2010-09-09 オークランド ユニサービシス リミテッド 成長ホルモンおよび関連ホルモンの阻害剤、ならびにそれらの使用方法
JP2011527560A (ja) * 2008-01-22 2011-11-04 アライム ファーマシューティカルズ,インコーポレーテッド 組織の損傷に関連した疾患及び障害を予防及び治療する、組織保護ペプチド及びペプチド類似体
US20180143202A1 (en) * 2016-08-05 2018-05-24 Sera Prognostics, Inc. Biomarkers for predicting preterm birth in a pregnant female exposed to progestogens
JP2020511633A (ja) * 2017-02-22 2020-04-16 ヘルステル・インコーポレイテッドHealthtell Inc. 感染のスクリーニング方法
JP2021510731A (ja) * 2018-01-15 2021-04-30 ラテラル、アイピー、プロプライエタリー、リミテッドLateral Ip Pty Ltd ペプチドおよびその使用
WO2019183686A1 (en) * 2018-03-29 2019-10-03 Lateral IP Pty Ltd Cyclic peptides and uses thereof
WO2020068990A1 (en) * 2018-09-26 2020-04-02 California Institute Of Technology Adeno-associated virus compositions for targeted gene therapy
EP3671210A1 (en) * 2018-12-21 2020-06-24 Biosystems International KFT Lung cancer protein epitomic biomarkers
WO2021127752A1 (en) * 2019-12-27 2021-07-01 Lateral IP Pty Ltd Cyclic peptide receptor lanthionine synthetase c-like protein (lancl) and uses thereof
RU2731919C1 (ru) * 2020-03-25 2020-09-09 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ коррекции микроциркуляции в плаценте пептидом, имитирующим альфа-спираль B эритропоэтина, при ADMA-подобной модели преэклампсии
RU2751964C1 (ru) * 2021-02-17 2021-07-21 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ снижения агрегационной способности тромбоцитов

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THE JOURNAL OF ORGANIC CHEMISTRY, vol. 35, no. 3, JPN6026021738, 1970, pages 867 - 868, ISSN: 0005872548 *

Also Published As

Publication number Publication date
CN117813105A (zh) 2024-04-02
AU2022316237A1 (en) 2024-02-01
US20250263435A1 (en) 2025-08-21
WO2023000038A1 (en) 2023-01-26
KR20240036634A (ko) 2024-03-20
EP4373509A4 (en) 2025-10-29
CA3226259A1 (en) 2023-01-26
EP4373509A1 (en) 2024-05-29

Similar Documents

Publication Publication Date Title
CN102686221B (zh) 治疗疼痛的方法
CA2817787C (en) Composition comprising a peptide and an inhibitor of viral neuraminidase
CA2796268A1 (en) Methods for treatment of sleep-related breathing disorders
JP2019512506A (ja) 呼吸器系疾患の治療のためのグルココルチコイドとポリエチレングリコール修飾インターロイキン2の組合せ
US20240082344A1 (en) Method of treating prader-willi syndrome
EP1896025B1 (en) Scopolamine for the treatment of depression and anxiety
US20250263435A1 (en) Peptide compositions capable of binding lanthionine synthetase c-like protein (lancl) and uses thereof
US20230256059A1 (en) Compositions for treating respiratory tract infection and uses thereof
US12492223B2 (en) Peptide compositions capable of binding lanthionine synthetase C-like protein (LanCl) and uses thereof
JP2017533967A (ja) システアミン組成物を用いるハンチントン病の処置方法
US20250255934A1 (en) Compositions for treating inflammatory airway disease and uses thereof
CA3047320A1 (en) Methods of administering hepcidin
CA2796207A1 (en) Compound for treatment of respiratory condition or disease
US20220273768A1 (en) Intranasal leptin compositions and methods of use thereof for prevention of opioid induced respiratory depression in obesity
EP3579923A1 (en) Treatment of asthma with cysteamine
WO2025037259A1 (en) Methods and compositions for preventing or treating severe asthma
TW202423407A (zh) 治療流感病毒之組合物及方法
WO2025255116A1 (en) Methods of treatment for opioid-induced ventilatory depression and muscle rigidity
US20110201659A1 (en) Agent for preventing or treating zoster-associated pain

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250718

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250718

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260529